首頁 > 市場調查報告書 > 製藥

癌症婦科治療

市場調查報告書

商品編碼

1870326

進行性卵巢癌市場按治療方法、給藥途徑、治療線、生物標記狀態、最終用戶和配銷通路分類 - 全球預測 2025-2032

Advanced Recurrent Ovarian Cancer Market by Treatment Type, Administration Route, Line Of Therapy, Biomarker Status, End User, Distribution Channel - Global Forecast 2025-2032

出版日期: 2025年09月30日 | 出版商:

360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

預計到 2032 年，進行性/復發性卵巢癌治療市場將成長至 32.2 億美元，複合年成長率為 9.70%。

關鍵市場統計數據
基準年 2024	15.3億美元
預計年份：2025年	16.8億美元
預測年份 2032	32.2億美元
複合年成長率 (%)	9.70%

重點關注不斷變化的臨床、監管和商業性環境，這些環境正在影響進行性和復發性卵巢癌利益相關人員的策略決策。

進行性和復發性卵巢癌的治療和商業環境瞬息萬變，臨床範式不斷轉變，相關利益者的關注度也日益提高。本執行摘要介紹了核心研究主題，重點闡述了標靶治療、生物標記指導治療和醫療服務模式的進步如何改變復發性疾病患者的治療路徑。此外，本概要還概述了監管壓力、支付方期望和供應鏈考量等因素如何與臨床進展交織在一起，共同影響商業性可行性。

精準診斷、不斷演變的給藥途徑以及支付方主導的證據要求如何重塑治療模式和商業化策略

進行性和復發性卵巢癌的治療模式正在經歷變革性變化，這主要得益於治療方法創新、精準診斷和重新設計的醫療服務模式。新型標靶治療和聯合治療正在重新定義療效預期和耐受性之間的平衡，而伴隨診斷和同源重組缺陷檢測的廣泛應用則使得個人化治療方案成為可能。因此，傳統的以化療為中心的治療路徑正在調整，優先考慮在分子層面適宜的情況下使用標靶藥物和免疫療法聯合治療。

2025年貿易政策變化對癌症藥物供應鏈韌性、採購慣例和商業性定位的策略影響

2025年關稅及不斷變化的貿易政策為進行性/復發性卵巢癌治療生態系統中的相關人員帶來了明顯的營運和策略複雜性。供應鏈經理和採購團隊正在重新評估其原料藥、成品和關鍵診斷劑的籌資策略，以降低成本波動和潛在的交貨延遲。因此，擁有垂直整合供應鏈和分散式製造地的公司能夠更靈活地應對關稅的短期影響，而其他公司則正在加快供應商合格和緊急時應對計畫的發展。

整合細分觀點：治療層級如何相互作用以影響採用趨勢

細分市場層面的洞察揭示了治療決策、劑量偏好、治療線定位、生物標記狀態、醫療環境和分銷合作夥伴如何共同塑造臨床和商業性發展軌跡。按治療類型分類，市場涵蓋化療（區分鉑類和非鉑類藥物）、荷爾蒙療法（包括Aromatase抑制劑和雌激素受體調節）、免疫療法（包括癌症疫苗和免疫查核點抑制劑）、作為關鍵干預手段的手術以及標靶治療（包括抗血管生成藥物和PARP抑制劑）。每類藥物都具有獨特的療效特徵、耐受性考量和實證醫學證據需求，這些因素都會影響其在臨床實踐中的應用。

一種針對葉酸受體α的新型雙特異性抗體在進行性和復發性卵巢癌的療效和安全性結果
PARP抑制劑維持治療在鉑敏感復發性卵巢癌的臨床應用率和臨床療效
利用同源重組缺陷檢測進行基於生物標記的患者分層，以最佳化復發性卵巢癌的治療選擇
對先前接受多種療法治療的卵巢癌患者，採用Bevacizumab單抗合併化療組合方案進行成本效益分析
抗體藥物複合體（ADC）臨床試驗進展：證實可改善晚期卵巢癌患者的總存活期

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章按治療方法進行性和復發性卵巢癌市場

化療
- 非鉑類藥物
- 含鉑類藥物
荷爾蒙療法
- Aromatase抑制劑
- 雌激素受體調節
免疫療法
- 癌症疫苗
- 查核點抑制劑
外科手術
標靶治療
- 抗血管新生藥物
- PARP抑制劑

第9章依給藥途徑分類的進行性/復發性卵巢癌市場

腹腔內給藥
靜脈注射
口服
皮下注射

第10章依治療線分類的進行性復發性卵巢癌市場

四線治療及以後
二級治療
三級治療

第11章依生物標記狀態進行性復發性卵巢癌市場

BRCA基因突變
同源重組缺陷陰性
同源重組缺陷陽性

第12章依最終用戶進行性復發性卵巢癌市場

門診治療中心
癌症中心
醫院
專科診所

第13章依分銷管道進行性復發性卵巢癌市場

醫院藥房
網路藥房
零售藥房

第14章各地區進行性復發性卵巢癌市場

美洲
- 北美洲
- 拉丁美洲
歐洲、中東和非洲
- 歐洲
- 中東
- 非洲
亞太地區

第15章依組別進行性復發性卵巢癌市場

ASEAN
GCC
EU
BRICS
G7
NATO

第16章各國進行性復發性卵巢癌市場

美國
加拿大
墨西哥
巴西
英國
德國
法國
俄羅斯
義大利
西班牙
中國
印度
日本
澳洲
韓國

第17章競爭格局

2024年市佔率分析
FPNV定位矩陣，2024
競爭分析
- AstraZeneca PLC
- GlaxoSmithKline plc
- Clovis Oncology, Inc.
- F. Hoffmann-La Roche AG
- LARVOL

簡介目錄圖表

Product Code: MRR-1A1A064BFFBB

The Advanced Recurrent Ovarian Cancer Market is projected to grow by USD 3.22 billion at a CAGR of 9.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.53 billion
Estimated Year [2025]	USD 1.68 billion
Forecast Year [2032]	USD 3.22 billion
CAGR (%)	9.70%

A focused orientation to the evolving clinical, regulatory, and commercial context that frames strategic decisions for advanced recurrent ovarian cancer stakeholders

Advanced recurrent ovarian cancer presents a rapidly evolving therapeutic and commercial environment defined by shifting clinical paradigms and intensifying stakeholder scrutiny. This executive summary introduces the core themes of the research, focusing on how advances in targeted modalities, biomarker-driven care, and care delivery models converge to change treatment pathways for patients with recurrent disease. The introduction also frames regulatory pressures, payer expectations, and supply chain considerations that intersect with clinical advances to shape commercial viability.

In addition, the introduction outlines the methodological approach and scope used to examine therapeutic classes, routes of administration, lines of therapy, biomarker-defined subpopulations, care settings, and distribution channels. By establishing a clear problem statement and analytical boundaries, the introduction prepares readers for the deeper analysis that follows, while highlighting the practical implications for development teams, commercial leaders, and investor groups. Ultimately, this section positions the reader to interpret subsequent insights with an understanding of clinical context and stakeholder priorities.

How precision diagnostics, administration route evolution, and payer-driven evidence requirements are reshaping treatment paradigms and commercialization strategies

The therapeutic landscape for advanced recurrent ovarian cancer is undergoing transformative shifts driven by therapeutic innovation, precision diagnostics, and care delivery redesign. Novel targeted therapies and combination regimens are redefining efficacy expectations and tolerability trade-offs, while companion diagnostics and broader adoption of homologous recombination deficiency testing are enabling more individualized treatment selection. As a result, traditional chemotherapy-dominant pathways are being recalibrated in favor of targeted agents and immunotherapy combinations where molecularly appropriate.

Concurrently, payer policies and real-world evidence requirements are prompting manufacturers to integrate health economics and outcomes research earlier in development. This trend increases the premium on robust, longitudinal outcome data and on demonstrating value across multiple lines of therapy. Moreover, the route of administration is becoming a strategic differentiator; therapies that enable oral or subcutaneous delivery offer advantages in patient convenience and outpatient management, thereby affecting adoption and channel preference. Taken together, these shifts require cross-functional alignment among clinical development, diagnostics partnerships, market access, and commercial operations to capture emerging opportunities effectively.

Strategic consequences of 2025 trade-policy shifts on supply chain resilience, procurement practices, and commercial positioning in oncology therapeutics

The introduction of tariffs and trade-policy shifts in 2025 has introduced discrete operational and strategic complexity for stakeholders across the advanced recurrent ovarian cancer ecosystem. Supply chain managers and procurement teams have responded by reassessing sourcing strategies for active pharmaceutical ingredients, finished products, and key diagnostic reagents to mitigate cost volatility and potential delivery delays. As a consequence, firms with vertically integrated supply chains or diversified manufacturing footprints have greater flexibility to absorb near-term tariff impacts, while others are accelerating supplier qualification and contingency planning.

From a commercial perspective, tariff-related cost pressures are increasing scrutiny on price versus value narratives when engaging payers and hospital procurement committees. Manufacturers are therefore prioritizing evidence generation that demonstrates real-world benefits, reductions in downstream resource use, and patient-centered outcomes to sustain favorable formulary positioning. In parallel, distributors and specialty pharmacies have re-evaluated inventory practices and freight optimization to maintain continuity of care for patients on critical therapies. In summary, tariff-driven dynamics have amplified the importance of resilient manufacturing, robust value communication, and proactive supply chain risk management.

Integrated segmentation perspective showing how treatment class, administration route, therapy line, biomarker-defined cohorts, care settings, and distribution channels interact to shape adoption

Segment-level insight reveals how therapeutic decisions, administration preferences, line-of-therapy placement, biomarker status, care settings, and distribution partners collectively shape clinical and commercial trajectories. Based on treatment type, the market spans chemotherapy-where differentiation exists between platinum based agents and non-platinum agents-hormone therapy including aromatase inhibitors and estrogen receptor modulators, immunotherapy comprising cancer vaccines and checkpoint inhibitors, surgery as a critical intervention, and targeted therapy that includes anti-angiogenic agents and PARP inhibitors; each class presents distinct efficacy profiles, tolerability considerations, and evidence-generation needs that influence adoption across clinical practices.

Based on administration route, therapeutic uptake is influenced by the balance between inpatient infusion requirements and the growing preference for oral or subcutaneous options that support outpatient care and patient convenience. Based on line of therapy, strategic positioning varies across fourth and beyond, second line, and third line settings, with organizations tailoring clinical development and sequencing studies to demonstrate meaningful benefit where unmet need and reimbursement potential intersect. Based on biomarker status, differentiation is most apparent in BRCA mutant populations and across homologous recombination deficiency positive and negative subgroups, which drive diagnostic integration and targeted therapy eligibility. Based on end user, adoption dynamics differ among ambulatory care centers, cancer centers, hospitals, and specialty clinics as each setting has unique clinical workflows, budget cycles, and procurement practices. Based on distribution channel, dynamics across hospital pharmacies, online pharmacies, and retail pharmacies affect patient access, channel economics, and adherence support strategies. Integrating these segmentation dimensions uncovers practical implications for clinical development, diagnostics alignment, pricing strategy, and channel-specific commercialization planning.

Regional imperatives and differentiated market entry strategies driven by payer diversity, diagnostic capacity, and regulatory variance across global geographies

Regional dynamics materially influence clinical pathways, regulatory expectations, diagnostic adoption, and commercialization approaches. In the Americas, payer heterogeneity and concentrated specialty pharmacy networks emphasize the importance of health economic evidence and patient support programs to secure coverage and access. In Europe, Middle East & Africa, diverse regulatory environments and reimbursement frameworks mean that market entry strategies must be tailored to national payer criteria and regional centers of excellence, while diagnostic infrastructure and access to molecular testing vary widely across the region. In the Asia-Pacific region, rapid expansion of diagnostic capabilities in certain countries and increasing public investment in oncology care create opportunities for early market entry, though local regulatory and pricing pressures often require adaptive commercialization models.

Consequently, successful regional strategies prioritize early stakeholder mapping, investment in diagnostic partnerships where biomarker-driven therapies matter most, and flexible channel strategies that reflect local distribution and reimbursement realities. Transitional considerations include local evidence generation to support formulary decisions and partnerships with regional clinical leaders to demonstrate real-world utility across diverse healthcare systems.

Competitive positioning shaped by clinical differentiation, diagnostics partnerships, and strategic alliances that enable precise patient targeting and payer engagement

Competitive dynamics in advanced recurrent ovarian cancer are concentrated among multinational pharmaceutical companies, specialized oncology biotechs, diagnostic firms that enable biomarker-guided care, and emerging contract manufacturing and distribution partners. Leading developers differentiate through clinical program design that emphasizes meaningful progression-free and patient-reported outcomes, the pursuit of biomarker-driven label expansions, and investment in companion diagnostics to secure precise patient populations. Biotech innovators frequently pursue combination regimens and novel mechanisms to address resistant disease, while established companies leverage scale, commercial infrastructure, and global regulatory experience to accelerate launch readiness.

Collaborations and licensing arrangements between therapeutic developers and diagnostic companies have become pivotal, enabling synchronized regulatory submissions and payer narratives. In addition, strategic alliances with specialty pharmacy networks and hospital systems support adherence programs and optimize channel-level distribution. Accordingly, companies that align clinical differentiation with a coherent diagnostics and access strategy will be better positioned to navigate complex reimbursement pathways and deliver sustained uptake in clinically appropriate patient cohorts.

Practical strategic steps industry leaders can implement to integrate diagnostics, bolster evidence generation, fortify supply chains, and accelerate payer acceptance across markets

Industry leaders should prioritize a set of actionable initiatives to capture therapeutic and commercial opportunities while mitigating risk. First, integrate biomarker strategy into clinical development from first-in-human through label-expansion studies to ensure timely companion-diagnostic availability and clear patient selection criteria. Second, invest in real-world evidence generation and health economics research early to support payer conversations and to demonstrate downstream value beyond traditional efficacy endpoints. Third, design development programs to consider administration route as a commercial differentiator, evaluating oral or subcutaneous formulations where clinically feasible to support outpatient care and adherence.

Furthermore, companies should strengthen supply chain resilience by diversifying sourcing, qualifying multiple manufacturing partners, and maintaining transparent logistics contingency plans to limit exposure to tariff or trade-policy disruptions. Establishing strong relationships with specialty pharmacies, hospital systems, and ambulatory care networks will facilitate access programs and channel-specific patient support. Finally, adopt a data-driven market access playbook that aligns evidence generation, pricing strategy, and stakeholder engagement across targeted regions to accelerate adoption and manage payer expectations effectively.

A transparent mixed-methods research approach combining primary expert insights, rigorous secondary source validation, and scenario analysis to ensure actionable findings

The research methodology underpinning this report integrates primary qualitative interviews with clinical experts, payers, and commercialization leaders, secondary literature review across peer-reviewed journals and regulatory documents, and structured synthesis of diagnostic and therapeutic pipelines. Primary input included semi-structured interviews with oncology clinicians, hospital pharmacists, and market access specialists to validate clinical pathways, identify adoption barriers, and surface payer evidence priorities. Secondary research encompassed regulatory guidance documents, clinical trial registries, and published outcome studies to corroborate therapeutic efficacy, safety profiles, and diagnostic utility.

Data synthesis applied triangulation methods to reconcile divergent perspectives and to distill practical implications for development and commercialization. The methodology also incorporated scenario analysis to explore supply chain and policy contingencies and expert validation rounds to ensure interpretive rigor. Transparency of assumptions and a documented audit trail of sources support reproducibility and enable clients to align the findings with internal evidence and strategic planning processes.

Consolidated insights emphasizing diagnostic-driven personalization, evidence-aligned development, and supply chain resilience as pillars for sustained commercial success

In conclusion, the advanced recurrent ovarian cancer ecosystem is at an inflection point where diagnostic-led personalization, therapeutic innovation, and payer-driven evidence demands intersect to reshape clinical and commercial pathways. Stakeholders that proactively integrate biomarker strategies, prioritize evidence generation aligned with payer needs, and optimize delivery models that favor patient-centric administration options will gain competitive advantage. Moreover, resilience in supply chain design and adaptive regional strategies are essential to navigate policy-related cost pressures and heterogeneous reimbursement landscapes.

Ultimately, the synthesis presented here should guide clinical development prioritization, commercialization sequencing, and cross-functional alignment to capture sustainable value. Decision-makers can use these insights to refine go-to-market plans, focus investment in high-impact evidence generation, and build partnerships that enhance diagnostic-enabled patient identification and access.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Efficacy and safety outcomes of novel bispecific antibodies targeting folate receptor alpha in advanced recurrent ovarian cancer
5.2. Real-world adoption rates and clinical impact of maintenance therapy with PARP inhibitors in platinum-sensitive recurrent ovarian cancer
5.3. Biomarker-driven patient stratification using homologous recombination deficiency testing to optimize treatment selection in recurrent ovarian cancer
5.4. Cost-effectiveness analysis of combination regimens involving bevacizumab and chemotherapy in heavily pretreated ovarian cancer patients
5.5. Clinical trial advancements in antibody drug conjugates demonstrating improved overall survival in late-line ovarian cancer therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Recurrent Ovarian Cancer Market, by Treatment Type

8.1. Chemotherapy
- 8.1.1. Non-Platinum Agents
- 8.1.2. Platinum Based Agents
8.2. Hormone Therapy
- 8.2.1. Aromatase Inhibitors
- 8.2.2. Estrogen Receptor Modulators
8.3. Immunotherapy
- 8.3.1. Cancer Vaccines
- 8.3.2. Checkpoint Inhibitors
8.4. Surgery
8.5. Targeted Therapy
- 8.5.1. Anti Angiogenic Agents
- 8.5.2. Parp Inhibitors

9. Advanced Recurrent Ovarian Cancer Market, by Administration Route

9.1. Intraperitoneal
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous

10. Advanced Recurrent Ovarian Cancer Market, by Line Of Therapy

10.1. Fourth And Beyond
10.2. Second Line
10.3. Third Line

11. Advanced Recurrent Ovarian Cancer Market, by Biomarker Status

11.1. BRCA Mutant
11.2. Homologous Recombination Deficiency Negative
11.3. Homologous Recombination Deficiency Positive

12. Advanced Recurrent Ovarian Cancer Market, by End User

12.1. Ambulatory Care Centers
12.2. Cancer Centers
12.3. Hospitals
12.4. Specialty Clinics

13. Advanced Recurrent Ovarian Cancer Market, by Distribution Channel

13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies

14. Advanced Recurrent Ovarian Cancer Market, by Region

14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
14.3. Asia-Pacific

15. Advanced Recurrent Ovarian Cancer Market, by Group

15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO

16. Advanced Recurrent Ovarian Cancer Market, by Country

16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea

17. Competitive Landscape

17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
- 17.3.1. AstraZeneca PLC
- 17.3.2. GlaxoSmithKline plc
- 17.3.3. Clovis Oncology, Inc.
- 17.3.4. F. Hoffmann-La Roche AG
- 17.3.5. LARVOL

簡介目錄圖表

LIST OF FIGURES

FIGURE 1. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2024 VS 2032 (%)
FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
FIGURE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
FIGURE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 15. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 16. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 17. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 19. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 20. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 21. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 24. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 25. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 26. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 27. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 28. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 29. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 31. ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

TABLE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2025-2032 (USD MILLION)
TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY REGION, 2025-2032 (USD MILLION)
TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY REGION, 2025-2032 (USD MILLION)
TABLE 43. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 45. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 47. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
TABLE 49. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
TABLE 51. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 53. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 55. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
TABLE 57. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 59. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 61. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
TABLE 63. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 65. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 67. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
TABLE 69. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 71. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 73. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
TABLE 75. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
TABLE 77. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 79. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 81. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
TABLE 83. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 85. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 87. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
TABLE 89. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 91. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 93. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
TABLE 95. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2032 (USD MILLION)
TABLE 97. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2025-2032 (USD MILLION)
TABLE 99. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 101. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
TABLE 103. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 105. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 107. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
TABLE 109. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
TABLE 111. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 113. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
TABLE 115. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 117. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 119. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
TABLE 121. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
TABLE 123. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
TABLE 125. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 127. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
TABLE 129. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 131. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 133. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
TABLE 135. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 137. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 139. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
TABLE 141. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY REGION, 2025-2032 (USD MILLION)
TABLE 143. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY GROUP, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY GROUP, 2025-2032 (USD MILLION)
TABLE 145. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BRAC MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 147. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
TABLE 149. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 151. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 153. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY REGION, 2025-2032 (USD MILLION)
TABLE 155. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 157. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 159. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 161. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
TABLE 163. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 165. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 167. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2032 (USD MILLION)
TABLE 169. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 171. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 173. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
TABLE 175. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 177. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 179. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
TABLE 181. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 183. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 185. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 187. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 188. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 189. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 190. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 191. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 192. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 193. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 194. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 195. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 196. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 197. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 198. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 199. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 200. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 201. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 202. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 203. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 204. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 205. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 206. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
TABLE 207. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
TABLE 209. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
TABLE 211. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
TABLE 213. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
TABLE 215. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
TABLE 217. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
TABLE 219. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
TABLE 221. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
TABLE 223. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
TABLE 225. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 227. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 229. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 230. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 231. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
TABLE 233. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 234. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
TABLE 235. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 236. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
TABLE 237. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
TABLE 239. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 240. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
TABLE 241. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 242. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
TABLE 243. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 244. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
TABLE 245. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 246. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
TABLE 247. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 249. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 251. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 252. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 253. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 254. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
TABLE 255. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
TABLE 257. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
TABLE 258. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
TABLE 259. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
TABLE 261. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 262. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
TABLE 263. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 264. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
TABLE 265. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 266. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
TABLE 267. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 268. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
TABLE 269. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 271. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFR